Revenue: As of FY2025 Q2, the actual value is USD 4.379 M.EPS: As of FY2025 Q2, the actual value is USD -5.13.<h3>Segment Revenue</h3><ul><li>Rental Income: $8,314,182 for the six months ended June 30, 2025, compared to $9,113,925 for the same period in 2024.</li><li>Fees and Other Income: $189,743 for the six months ended June 30, 2025, compared to $262,678 for the same period in 2024.</li></ul><h3>Operational Metrics</h3><ul><li>Net Income (Loss): - $2,670,705 for the six months ended June 30, 2025, compared to - $15,116,470 for the same period in 2024.</li><li>Depreciation and Amortization: $2,455,796 for the six months ended June 30, 2025, compared to $2,702,388 for the same period in 2024.</li><li>General and Administrative Expenses: $2,885,634 for the six months ended June 30, 2025, compared to $4,287,366 for the same period in 2024.</li><li>Rental Operating Costs: $3,075,248 for the six months ended June 30, 2025, compared to $3,056,072 for the same period in 2024.</li><li>Impairment of Goodwill and Real Estate Assets: $4,344,332 for the six months ended June 30, 2025, compared to $196,793 for the same period in 2024.</li><li>Interest Expense - Mortgage Notes: - $2,988,341 for the six months ended June 30, 2025, compared to - $3,041,051 for the same period in 2024.</li></ul><h3>Cash Flow</h3><ul><li>Net Cash Used in Operating Activities: - $1,012,227 for the six months ended June 30, 2025, compared to - $1,301,028 for the same period in 2024.</li><li>Net Cash Provided by Investing Activities: $11,372,797 for the six months ended June 30, 2025, compared to $12,960,482 for the same period in 2024.</li><li>Net Cash Used in Financing Activities: - $11,111,977 for the six months ended June 30, 2025, compared to - $9,635,001 for the same period in 2024.</li></ul><h3>Unique Metrics</h3><ul><li>Gain on Sales of Real Estate, Net: $4,777,327 for the six months ended June 30, 2025, compared to $2,829,998 for the same period in 2024.</li><li>Net Loss in Conduit Pharmaceuticals Marketable Securities: - $184,459 for the six months ended June 30, 2025, compared to - $13,888,667 for the same period in 2024.</li></ul><h3>Future Outlook and Strategy</h3><ul><li>Core Business Focus: The company plans to continue pursuing value-creating investments and returning capital to stockholders through a repurchase program. The Board of Directors authorized a stock repurchase program of up to $6.0 million of outstanding shares of Series A Common Stock and up to $4.0 million of Series D Preferred Stock, which shall expire in December 2025.</li><li>Non-Core Business: The company is exploring strategic alternatives through its Strategic Planning and Cyber Committee, which may include acquisitions, dispositions, and other strategic initiatives to enhance shareholder value.</li><li>Priority: The company intends to use net proceeds from recent offerings for working capital and other general corporate purposes, including potentially acquiring additional properties.</li></ul>

PRESIDIO PPTY TR INC C/WTS 24/01/2027(TO PUR COM) | 10-Q: FY2025 Q2 Revenue: USD 4.379 M